- Home
- GROY vs OMER Comparison
GROY vs OMER Comparison
Compare GROY & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROY | OMER |
|---|---|---|
| Founded | 2020 | 1994 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 741.4M | 844.6M |
| IPO Year | 2020 | 2008 |
Fundamental Metrics
Financial Performance| Metric | GROY | OMER |
|---|---|---|
| Price | $3.52 | $19.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $5.90 | ★ $32.50 |
| AVG Volume (30 Days) | ★ 2.5M | 2.4M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | $145.80 | N/A |
| Revenue Next Year | $60.03 | $233.22 |
| P/E Ratio | ★ N/A | $25.09 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.45 | $3.94 |
| 52 Week High | $5.45 | $19.58 |
Technical Indicators
Market Signals| Indicator | GROY | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 71.70 | 86.30 |
| Support Level | $3.29 | $9.12 |
| Resistance Level | $3.89 | N/A |
| Average True Range (ATR) | 0.11 | 0.84 |
| MACD | 0.04 | 0.41 |
| Stochastic Oscillator | 85.53 | 96.99 |
Price Performance
Historical ComparisonAbout GROY Gold Royalty Corp.
Gold Royalty Corp is principally engaged in acquiring gold-focused royalties, streaming, and similar interests. It is a gold-focused royalty company offering creative financing solutions to the metals and mining industry. The Company operates in Bosnia and Herzegovina, Canada, which generates maximum revenue, the USA, Brazil, and Mexico.
About OMER Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.